Real-world clinical outcomes and treatment patterns among patients with triple-class exposed multiple myeloma: an analysis using the Connect® multiple myeloma disease registry

被引：0
|
作者：
Lee, Hans [1 ]
Ailawadhi, Sikander [2 ]
Dhanda, Devender [3 ]
Patwardhan, Pallavi [3 ]
Yu, Edward [3 ]
Liu, Liang [3 ]
Rifkin, Robert [4 ]
Terebelo, Howard [5 ]
Abonour, Rafat [6 ]
Narang, Mohit [7 ]
Gasparetto, Cristina [8 ]
Toomey, Kathleen [9 ]
Hardin, James [10 ]
Durie, Brian [11 ]
Jagannath, Sundar [12 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr Houston, Dept Lymphoma Myeloma, Houston, TX USA
[2] Mayo Clin, Jacksonville, FL USA
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] US Oncol Res, Rocky Mt Canc Ctr, Denver, CO USA
[5] Ascens Providence Hosp, Southfield, MI USA
[6] Indiana Univ Sch Med, Indianapolis, IN USA
[7] Maryland Oncol Hematol, Columbia, MD USA
[8] Duke Univ, Sch Med, Durham, NC USA
[9] Steeplechase Canc Ctr, Somerville, NJ USA
[10] Univ South Carolina, Arnold Sch Publ Hlth, Columbia, SC USA
[11] Cedars Sinai Samuel Oschin Canc Ctr, Los Angeles, CA USA
[12] Mt Sinai Med Ctr, New York, NY USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-285
引用
收藏
页码：S193 / S194
页数：2
相关论文
共 50 条
  • [41] Treatment patterns and outcomes of patients with triple-class exposed relapsed or refractory multiple myeloma: analysis of the Optum electronic health records and commercial claims database
    Kumar, Shaji
    Nair, Sandhya
    Lin, Xiwu
    Marshall, Alexander
    Slavcev, Mary
    Potluri, Ravi
    Chari, Ajai
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S183 - S183
  • [42] Comparative effectiveness of teclistamab versus real-world physician's choice of therapy for patients with triple-class exposed relapsed/refractory multiple myeloma
    Krishnan, Amrita
    Nooka, Ajay
    Chari, Ajai
    Garfall, Alfred
    Martin, Thomas
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Londhe, Anil
    Pei, Lixia
    Ammann, Eric
    Kobos, Rachel
    Smit, Jennifer
    Parekh, Trilok
    Marshall, Alexander
    Slavcev, Mary
    Usmani, Saad
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S174 - S174
  • [43] Real-world treatment patterns and outcomes in lenalidomide refractory multiple myeloma patients in Europe: a real-world survey
    Martinez-Lopez, Joaquin
    Mendes, Joao
    Luke, Emily
    Kluth, Caspian
    Salmon, Phoebe
    Bailey, Abigail
    Ribbands, Amanda
    Gay, Francesca
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S198 - S199
  • [44] Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis
    Shebli Atrash
    Evelyn M. Flahavan
    Tao Xu
    Esprit Ma
    Sudeep Karve
    Wan-Jen Hong
    Gilbert Jirau-Lucca
    Michael Nixon
    Sikander Ailawadhi
    [J]. Blood Cancer Journal, 12
  • [45] Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis
    Atrash, Shebli
    Flahavan, Evelyn M.
    Xu, Tao
    Ma, Esprit
    Karve, Sudeep
    Hong, Wan-Jen
    Jirau-Lucca, Gilbert
    Nixon, Michael
    Ailawadhi, Sikander
    [J]. BLOOD CANCER JOURNAL, 2022, 12 (03)
  • [46] Real-world treatment patterns and outcomes of triple-exposed multiple myeloma patients treated in community oncology practices in the United States.
    Smith, Robert
    Xue, Mei
    Dorrow, Natalie
    Varughese, Prateesh
    Hogea, Cosima
    Buckingham, Trudy
    Sansbury, Leah
    Ferrante, Shannon
    Maiese, Eric M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma
    Bruno, Amanda S.
    Willson, Jenny L.
    Opalinska, Joanna M.
    Nelson, Jeanenne J.
    Lunacsek, Orsolya E.
    Stafkey-Mailey, Dana R.
    Willey, Joanne P.
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (09) : 1017 - 1025
  • [48] Current real-world treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma.
    Willson, Jenny
    Bruno, Amanda
    Opalinska, Joanna
    Nelson, Jeanenne Joy
    Lunacsek, Orsolya
    Stafkey-Mailey, Dana
    Willey, Joanne P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Outcomes of Patients with Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from the LocoMMotion plus MoMMent Studies
    Moreau, Philippe
    Mateos, Maria-Victoria
    Goldschmidt, Hartmut
    Gonzalez Garcia, Esther
    Besemer, Britta
    Gonzalez Perez, Marta Sonia
    Mohty, Mohamad
    Lindsey-Hill, Joanne
    Kirkpatrick, Suriya
    Delforge, Michel
    Angelucci, Emanuele
    Di Raimondo, Francesco
    Vij, Ravi
    Doyle, Margaret
    Gray, Kathleen
    Albrecht, Claire
    Strulev, Vadim
    Haddad, Imene
    Saarinen, Silva
    Mitchell, Lada
    Buyze, Jozefien
    Weisel, Katja
    [J]. BLOOD, 2023, 142
  • [50] From triple-class exposed (TCE) to penta-exposed and triple-class refractory (PE-TCR): Real-world outcomes across a spectrum of advanced relapsed or refractory multiple myeloma (RRMM) patients (Pts) in the United States.
    Delea, Thomas E.
    Song, Xue
    Ge, Wenzhen
    Chi, Lei
    Eichten, Caitlin
    Moynahan, Aaron
    Weycker, Derek
    Ma, Qiufei
    Kroog, Glenn Scott
    Rodriguez-Lorenc, Karen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345